FDA’s Cannabis Derived Products Data Acceleration Plan
Submitted by csteele on Wed, 10/27/2021 - 13:30
The U.S. Food and Drug Administration’s (FDA) has released a new plan to leverage novel data sources and advanced data analytics to identify current and emerging safety vulnerabilities in the "Cannabis-Derived Products" market.
The plan addresses CBD and other emerging cannabinoids such as delta-8-tetrahydrocannabinol (Delta-8 THC), delta-10 tetrahydrocannabinol (Delta-10 THC), cannabinol (CBN), tetrahydrocannabivarin (THCV), and cannabigerol (CBG), among others.
File attachments:
